Timothy Vollmer, DO
Interventional Pain Medicine · Saint Marys, PANPI 1851644637
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,731 of the $4,454 with a category attached, or 61.3%. 9 manufacturers reported payments, led by Abbott at 45.3% of the total.
Across 72 payments — averaging $61.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$2K
- Si-bone, Inc.$1K
- Pacira Pharmaceuticals Incorporated$741
- Boston Scientific$138
- Medtronic$133
- Bioventus LLC$96
- plus $67 from 3 others
What the payments were for
- Travel & lodging$1,72339%
- Food & beverage$2,73161%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 43 | $2,018 |
| Si-bone, Inc. | 10 | $1,262 |
| Pacira Pharmaceuticals Incorporated | 4 | $741 |
| Boston Scientific | 5 | $138 |
| Medtronic | 3 | $133 |
| Bioventus LLC | 4 | $96 |
| Amgen | 1 | $39 |
| Pacira Therapeutics, Inc. | 1 | $16 |
| Foundation Fusion Solutions, LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- IFUSE IMPLANT SYSTEM$1,000
- IOVERA SYSTEM$338
- EXPAREL$328
- Proclaim Family of SCS IPGs$164
- PROCLAIM$147
How this compares
$4,454 in reported general payments places this provider in the 60th percentile of 59 interventional pain medicine providers in Pennsylvania.
See all interventional pain medicine providers in Pennsylvania →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gabapentin | 207 | $3,519 |
| Duloxetine Hcl | 50 | $1,009 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 50 | $837 |
| Nortriptyline Hcl | 24 | $584 |
| Celecoxib | 15 | $354 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 119 | $336 |
| Tramadol Hcl | 48 | $297 |
| Mupirocin | 23 | $193 |
| Meloxicam | 29 | $182 |
| Pregabalin | 13 | $152 |
| Topiramate | 21 | $135 |
| Lorazepam | 125 | $68 |
Paid to pharmacies, not to this prescriber.
Other interventional pain medicine in Saint Marys
- Michael FishmanLebanon$670K
- David ProvenzanoSewickley$198K
- Michael FarrellPittsburgh$23K
- Farshad RashidianWest Chester$19K
- Chad MetzgerDarby$14K
- Jorge Rivero-BecerraPittsburgh$12K
- James BresnahanSpringfield$12K
- Jonathan SchollIndiana$11K
- Nathan MaltezosWest Chester$10K
- Mark BellPlains$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.